Prodrug Strategies for Paclitaxel

Paclitaxel is an anti-tumor agent with remarkable anti-tumor activity and wide clinical uses. However, it is also faced with various challenges especially for its poor water solubility and low selectivity for the target. To overcome these disadvantages of paclitaxel, approaches using small molecule...

Descripción completa

Detalles Bibliográficos
Autores principales: Meng, Ziyuan, Lv, Quanxia, Lu, Jun, Yao, Houzong, Lv, Xiaoqing, Jiang, Feng, Lu, Aiping, Zhang, Ge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881612/
https://www.ncbi.nlm.nih.gov/pubmed/27223283
http://dx.doi.org/10.3390/ijms17050796
_version_ 1782433997427572736
author Meng, Ziyuan
Lv, Quanxia
Lu, Jun
Yao, Houzong
Lv, Xiaoqing
Jiang, Feng
Lu, Aiping
Zhang, Ge
author_facet Meng, Ziyuan
Lv, Quanxia
Lu, Jun
Yao, Houzong
Lv, Xiaoqing
Jiang, Feng
Lu, Aiping
Zhang, Ge
author_sort Meng, Ziyuan
collection PubMed
description Paclitaxel is an anti-tumor agent with remarkable anti-tumor activity and wide clinical uses. However, it is also faced with various challenges especially for its poor water solubility and low selectivity for the target. To overcome these disadvantages of paclitaxel, approaches using small molecule modifications and macromolecule modifications have been developed by many research groups from all over the world. In this review, we discuss the different strategies especially prodrug strategies that are currently used to make paclitaxel more effective.
format Online
Article
Text
id pubmed-4881612
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-48816122016-05-27 Prodrug Strategies for Paclitaxel Meng, Ziyuan Lv, Quanxia Lu, Jun Yao, Houzong Lv, Xiaoqing Jiang, Feng Lu, Aiping Zhang, Ge Int J Mol Sci Review Paclitaxel is an anti-tumor agent with remarkable anti-tumor activity and wide clinical uses. However, it is also faced with various challenges especially for its poor water solubility and low selectivity for the target. To overcome these disadvantages of paclitaxel, approaches using small molecule modifications and macromolecule modifications have been developed by many research groups from all over the world. In this review, we discuss the different strategies especially prodrug strategies that are currently used to make paclitaxel more effective. MDPI 2016-05-23 /pmc/articles/PMC4881612/ /pubmed/27223283 http://dx.doi.org/10.3390/ijms17050796 Text en © 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Meng, Ziyuan
Lv, Quanxia
Lu, Jun
Yao, Houzong
Lv, Xiaoqing
Jiang, Feng
Lu, Aiping
Zhang, Ge
Prodrug Strategies for Paclitaxel
title Prodrug Strategies for Paclitaxel
title_full Prodrug Strategies for Paclitaxel
title_fullStr Prodrug Strategies for Paclitaxel
title_full_unstemmed Prodrug Strategies for Paclitaxel
title_short Prodrug Strategies for Paclitaxel
title_sort prodrug strategies for paclitaxel
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881612/
https://www.ncbi.nlm.nih.gov/pubmed/27223283
http://dx.doi.org/10.3390/ijms17050796
work_keys_str_mv AT mengziyuan prodrugstrategiesforpaclitaxel
AT lvquanxia prodrugstrategiesforpaclitaxel
AT lujun prodrugstrategiesforpaclitaxel
AT yaohouzong prodrugstrategiesforpaclitaxel
AT lvxiaoqing prodrugstrategiesforpaclitaxel
AT jiangfeng prodrugstrategiesforpaclitaxel
AT luaiping prodrugstrategiesforpaclitaxel
AT zhangge prodrugstrategiesforpaclitaxel

Ejemplares similares